HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase 1 trial and assay of rubidazone (NSC 164011) in patients with advanced solid tumors.

Abstract
A new high-pressure liquid chromatographic method was developed for the simultaneous determination of rubidazone and daunorubicin in human plasma at concentrations as low as 60 ng/ml. Clinical toxicity and the stability of rubidazone were studied in nine patients with advanced solid tumors. Rubidazone was administered by i.v. infusion over 1 hr on a single day every 4 weeks. Moderate leukopenia was the dose-limiting toxicity in four of six patients treated at 150 mg sq/m. Assay of rubidazone in plasma samples obtained after administration of rubidazone showed that the drug was stable for at least 7 hr.
AuthorsJ S Kovach, M M Ames, M L Sternad, M J O'Connell
JournalCancer research (Cancer Res) Vol. 39 Issue 3 Pg. 823-8 (Mar 1979) ISSN: 0008-5472 [Print] United States
PMID427770 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Daunorubicin
Topics
  • Adult
  • Chromatography, High Pressure Liquid
  • Daunorubicin (analogs & derivatives, blood, toxicity)
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Parenteral
  • Leukopenia (chemically induced)
  • Male
  • Middle Aged
  • Neoplasms (drug therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: